Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Intrinsic Value
Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. [ Read More ]
The intrinsic value of one ZYDUSLIFE stock under the Base Case scenario is 557.89 INR. Compared to the current market price of 983.65 INR, Zydus Lifesciences Ltd is Overvalued by 43%.
Valuation Backtest
Zydus Lifesciences Ltd
Run backtest to discover the historical profit from buying and selling ZYDUSLIFE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Zydus Lifesciences Ltd
Current Assets | 99.3B |
Cash & Short-Term Investments | 25.8B |
Receivables | 39.2B |
Other Current Assets | 34.4B |
Non-Current Assets | 159.4B |
Long-Term Investments | 11.3B |
PP&E | 69.4B |
Intangibles | 58.6B |
Other Non-Current Assets | 20.2B |
Current Liabilities | 43.6B |
Accounts Payable | 16.4B |
Other Current Liabilities | 27.3B |
Non-Current Liabilities | 27.8B |
Long-Term Debt | 307m |
Other Non-Current Liabilities | 27.5B |
Earnings Waterfall
Zydus Lifesciences Ltd
Revenue
|
186.8B
INR
|
Cost of Revenue
|
-63.1B
INR
|
Gross Profit
|
123.7B
INR
|
Operating Expenses
|
-84.6B
INR
|
Operating Income
|
39.1B
INR
|
Other Expenses
|
-9.4B
INR
|
Net Income
|
29.7B
INR
|
Free Cash Flow Analysis
Zydus Lifesciences Ltd
ZYDUSLIFE Profitability Score
Profitability Due Diligence
Zydus Lifesciences Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Zydus Lifesciences Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
ZYDUSLIFE Solvency Score
Solvency Due Diligence
Zydus Lifesciences Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Score
Zydus Lifesciences Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZYDUSLIFE Price Targets Summary
Zydus Lifesciences Ltd
According to Wall Street analysts, the average 1-year price target for ZYDUSLIFE is 816.28 INR with a low forecast of 494.9 INR and a high forecast of 1 162.35 INR.
Shareholder Return
ZYDUSLIFE Price
Zydus Lifesciences Ltd
Average Annual Return | 19.64% |
Standard Deviation of Annual Returns | 47.53% |
Max Drawdown | -18% |
Market Capitalization | 994.8B INR |
Shares Outstanding | 1 006 230 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The company is headquartered in Ahmedabad, Gujarat and currently employs 23,743 full-time employees. The firm is focused on delivering care and nurturance for the patients, backed by science and cutting-edge technology. The firm has a pipeline for Biologics and Vaccines. The firm offers Lipaglyn to treat diabetic dyslipidemia. The company offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The firm in collaboration with Medicines for Malaria Venture (MMV) is developing ZY19489, a single dose cure for Malaria. The Company’s novel oral small molecule, ZYIL1, is an NLRP3 inhibitor candidate. Its ZyCoV-D is a plasmid Deoxyribonucleic acid (DNA) Vaccine for human use. The firm provides Twinrab, which is a novel biological entity for rabies post-exposure prophylaxis. The firm has operations globally and is present in approximately 55 countries worldwide, with 36 manufacturing plants and eight research and development centers.
Contact
IPO
Employees
Officers
The intrinsic value of one ZYDUSLIFE stock under the Base Case scenario is 557.89 INR.
Compared to the current market price of 983.65 INR, Zydus Lifesciences Ltd is Overvalued by 43%.